476 related articles for article (PubMed ID: 31746102)
1. Structure-Based Design of a Macrocyclic PROTAC.
Testa A; Hughes SJ; Lucas X; Wright JE; Ciulli A
Angew Chem Int Ed Engl; 2020 Jan; 59(4):1727-1734. PubMed ID: 31746102
[TBL] [Abstract][Full Text] [Related]
2. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate.
Roy MJ; Winkler S; Hughes SJ; Whitworth C; Galant M; Farnaby W; Rumpel K; Ciulli A
ACS Chem Biol; 2019 Mar; 14(3):361-368. PubMed ID: 30721025
[TBL] [Abstract][Full Text] [Related]
3. Uncovering the Kinetic Characteristics and Degradation Preference of PROTAC Systems with Advanced Theoretical Analyses.
Tang R; Wang Z; Xiang S; Wang L; Yu Y; Wang Q; Deng Q; Hou T; Sun H
JACS Au; 2023 Jun; 3(6):1775-1789. PubMed ID: 37388700
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of PROTAC cooperative recognition for selective protein degradation.
Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
6. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
7. Crystallization of VHL-based PROTAC-induced ternary complexes.
Wijaya AJ; Farnaby W; Ciulli A
Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
[TBL] [Abstract][Full Text] [Related]
8. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Tarantelli C; Cannas E; Ekeh H; Moscatello C; Gaudio E; Cascione L; Napoli S; Rech C; Testa A; Maniaci C; Rinaldi A; Zucca E; Stathis A; Ciulli A; Bertoni F
Explor Target Antitumor Ther; 2021; 2(6):586-601. PubMed ID: 36046113
[TBL] [Abstract][Full Text] [Related]
9. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
[TBL] [Abstract][Full Text] [Related]
10. Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins.
Sindhikara D; Wagner M; Gkeka P; Güssregen S; Tiwari G; Hessler G; Yapici E; Li Z; Evers A
J Med Chem; 2020 Oct; 63(20):12100-12115. PubMed ID: 33017535
[TBL] [Abstract][Full Text] [Related]
11. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity.
Imaide S; Riching KM; Makukhin N; Vetma V; Whitworth C; Hughes SJ; Trainor N; Mahan SD; Murphy N; Cowan AD; Chan KH; Craigon C; Testa A; Maniaci C; Urh M; Daniels DL; Ciulli A
Nat Chem Biol; 2021 Nov; 17(11):1157-1167. PubMed ID: 34675414
[TBL] [Abstract][Full Text] [Related]
12. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of BRD4 degraders.
Ding M; Shao Y; Sun D; Meng S; Zang Y; Zhou Y; Li J; Lu W; Zhu S
Bioorg Med Chem; 2023 Jan; 78():117134. PubMed ID: 36563515
[TBL] [Abstract][Full Text] [Related]
15. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C; Hu Y; Zhou B; Fernandez-Salas E; Yang CY; Liu L; McEachern D; Przybranowski S; Wang M; Stuckey J; Meagher J; Bai L; Chen Z; Lin M; Yang J; Ziazadeh DN; Xu F; Hu J; Xiang W; Huang L; Li S; Wen B; Sun D; Wang S
J Med Chem; 2018 Aug; 61(15):6685-6704. PubMed ID: 30019901
[TBL] [Abstract][Full Text] [Related]
16. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
Zengerle M; Chan KH; Ciulli A
ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
[TBL] [Abstract][Full Text] [Related]
17. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.
Krieger J; Sorrell FJ; Wegener AA; Leuthner B; Machrouhi-Porcher F; Hecht M; Leibrock EM; Müller JE; Eisert J; Hartung IV; Schlesiger S
ChemMedChem; 2023 Apr; 18(8):e202200615. PubMed ID: 36749883
[TBL] [Abstract][Full Text] [Related]
18. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
[TBL] [Abstract][Full Text] [Related]
19. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
[TBL] [Abstract][Full Text] [Related]
20. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation.
Wurz RP; Rui H; Dellamaggiore K; Ghimire-Rijal S; Choi K; Smither K; Amegadzie A; Chen N; Li X; Banerjee A; Chen Q; Mohl D; Vaish A
Nat Commun; 2023 Jul; 14(1):4177. PubMed ID: 37443112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]